Charles River Laboratories International (CRL) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories First Quarter twenty twenty five Earnings Conference Call. This call is being recorded. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. I would now like to turn the conference over to our host, Todd Spencer, Vice President of ...

Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.59%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $2.50 per share when it actually produced earnings of $2.66, delivering a surprise ...

Charles River Laboratories 1Q 2025 Results May 7, 2025 © 2025 Charles River Laboratories International, Inc. Safe Harbor Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that p ...

Exhibit 99.1 – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – WILMINGTON, MA, May 7, 2025 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. Th ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Charles River Laboratories (CRL) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on M ...

Charles River Laboratories International, Inc. (CRL) is scheduled to report first-quarter 2025 results on May 7, before market open.In the last reported quarter, the company’s adjusted earnings per share (EPS) of $2.66 surpassed the Zacks Consensus Estimate by 6.4%. Earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 10.22%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)CRL’s Q1 EstimatesThe Zacks Consensus Estimate for revenues is ...

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise.As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vas ...

It’s been a turbulent start to 2025 for investors. The market has faced a wave of selling pressure driven by surging tariffs, escalating geopolitical tensions, and growing fears of a global economic slowdown. The S&P 500, tracked by the popular SPDR ETF NYSEARCA: SPY, is now down 8% year-to-date and more than 12% off its 52-week high. However, there has been a glimmer of relief. After former President Trump announced a 90-day tariff pause for countries that refrained from retaliating against the U.S., the m ...

Charles River Laboratories (CRL) shares rallied 6.9% in the last trading session to close at $106.60. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 41.7% loss over the past four weeks.Charles River scored a strong price increase on investors’ optimism driven by the company’s impending first-quarter 2025 results, expected to release on May 8 before the market opens. In the last reported fourth quarter, both ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Charles River Laboratories (CRL) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This medical research equipment and services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 6.49%.For the ...